Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Multiple Oral Administration in Japanese Healthy Adult Male Subjects

Next Previous
X
Search
Trial Profile

A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Multiple Oral Administration in Japanese Healthy Adult Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esaxerenone (Primary)
  • Indications Diabetic nephropathies; Essential hypertension; Hyperaldosteronism; Hypertension
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 24 Apr 2018 Results of pooled data from two phase1 single and multiple dose trial (JapicCTI163473 and JapicCTI163476) assessing pharmacokinetics, pharmacodynamics, and safety of oral esaxerenone in healthy Japanese subjects, were published in the British Journal of Clinical Pharmacology.
    • 27 Dec 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top